Advances in VHL Disease and HIF2a Inhibitors: Insights from Recent Research with Othon Iliopoulos, MD, PhD
November 14 @ 6:30 pm - 7:30 pm EST
FreeDate & Time: Nov 14th, 6:30 pm EST
Location: Zoom (Link to be provided upon registration)
Join us for an informative webinar featuring renowned VHL researcher Dr. Othon Iliopoulos as he delves into the latest advancements in understanding Von Hippel-Lindau (VHL) disease and the role of HIF2a inhibitors in treatment.
Dr. Iliopoulos will present key insights from his recently published article, “Updated Findings with Belzutifan in Von Hippel-Lindau Disease-Associated CNS Hemangioblastomas,” highlighting the significant impacts of belzutifan on patient outcomes. He will discuss the mechanisms of VHL disease, the role of HIF2a in tumorigenesis, and the therapeutic potential of HIF2a inhibitors.
Key Topics:
- Overview of VHL disease and its implications
- Mechanism of action of HIF2a inhibitors
- Recent clinical findings and their relevance for patient care
- Future directions in VHL disease research and treatment strategies
This webinar is an excellent opportunity for healthcare professionals, researchers, and anyone interested in the latest developments in VHL disease to engage with Dr. Iliopoulos and gain valuable insights into ongoing research and clinical applications.
Register now to secure your spot and be part of this engaging discussion!